Skip to content

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

COPD (Chronic Obstructive Pulmonary Disease)

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to:

* Perform lung function and exercise tests
* Have ultrasound of their heart
* Have CT images of their lungs
* Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic)

The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    50 to 85

Critères de participation

Inclusion Criteria:

* Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted

Exclusion Criteria:

* Pre-existing heart failure and pulmonary artery hypertension.
* Known thrombocytopenia.
* Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic.
* Known sensitivity to prostanoids
* Severe hepatic insufficiency

Lieu de l'étude

Clinical Physiology Laboratory
Clinical Physiology Laboratory
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Desi Fuhr, MSc

[email protected]
7804926720
Backup Contact

Michael Stickland, PhD

[email protected]
7804923995
Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: NCT06969573